✦ LIBER ✦

Pharmacokinetics and Pharmacodynamics of TBR-652, a Novel CCR5 Antagonist, in HIV-1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naive Patients

✍ Scribed by Marier, J.-F.; Trinh, M.; Pheng, L. H.; Palleja, S. M.; Martin, D. E.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Potent Inhibition of HIV-1 Infectivity i

✍ Simmons, G. 📂 Article 📅 1997 🏛 American Association for the Advancement of Scienc 🌐 English ⚖ 432 KB

Detection of HIV-1 CXCR4 tropism and res

✍ Paul McNicholas; Regis A. Vilchez; Wayne Greaves; Sushma Kumar; Chinyere Onyebuc 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 500 KB

Efficacy of short-term monotherapy with

✍ Fätkenheuer, Gerd; Pozniak, Anton L; Johnson, Margaret A; Plettenberg, Andreas; 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 163 KB

Antiviral activity and safety of aplavir

✍ P Yeni; A LaMarca; D Berger; P Cimoch; A Lazzarin; P Salvato; FM Smaill; E Teofi 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 233 KB

Case Studies in Modern Drug Discovery an

✍ Huang, Xianhai; Aslanian, Robert G. 📂 Article 📅 2012 🏛 John Wiley & Sons, Inc. ⚖ 603 KB

SCH-C (SCH 351125), an orally bioavailab

✍ Strizki, J. M.; Xu, S.; Wagner, N. E.; Wojcik, L.; Liu, J.; Hou, Y.; Endres, M.; 📂 Article 📅 2001 🏛 National Academy of Sciences 🌐 English ⚖ 149 KB